Hypercoagulation after neoadjuvant immunochemotherapy as a new prognostic indicator in patients with locally advanced gastric cancer undergoing surgery

doi:10.4251/wjgo.v17.i3.100927

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (191)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-3)

Sum=161

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=21

Mar 15, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Mar 15, 2025; 17(3): 100927
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.100927

Open in New Tab Full Size Figure Download Figure

Figure 1 Flow diagram for screening participants. LAGC: Locally advanced gastric cancer.

Open in New Tab Full Size Figure Download Figure

Figure 2 Comparison of overall survival according to pretherapeutic coagulation factors. A: Overall survival (OS) associated with pretherapeutic plasma D-dimer and fibrinogen concentrations; B: Comparison of OS between pretherapeutic hypercoagulation and non-hypercoagulation; C: Comparison among pretherapeutic non-hypercoagulation, high concentrations of either (either elevated), and high concentrations of both (both elevated) after neoadjuvant immunochemotherapy.

Open in New Tab Full Size Figure Download Figure

Figure 3 Comparison of overall survival according to preoperative coagulation factors. A: Overall survival (OS) associated with preoperative plasma D-dimer and fibrinogen concentrations; B: Comparison of OS between preoperative hypercoagulation and non-hypercoagulation; C: Comparison among preoperative non-hypercoagulation, high concentrations of either (either elevated), and high concentrations of both (both elevated) after neoadjuvant immunochemotherapy.

Open in New Tab Full Size Figure Download Figure

Figure 4 Comparison of recurrence according to levels of preoperative coagulation factors. A: Disease-free survival (DFS) associated with preoperative D-dimer and fibrinogen concentrations; B: Comparison of DFS between hypercoagulation and non-hypercoagulation; C: Frequency of the recurrences in each coagulation group.

Citation: Li TH, Sun X, Li CG, Yin YP, Tao KX. Hypercoagulation after neoadjuvant immunochemotherapy as a new prognostic indicator in patients with locally advanced gastric cancer undergoing surgery. World J Gastrointest Oncol 2025; 17(3): 100927
URL: https://www.wjgnet.com/1948-5204/full/v17/i3/100927.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i3.100927